Market closedNon-fractional
Inotiv/NOTV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Inotiv
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Ticker
NOTV
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
West Lafayette, United States
Employees
2,005
Website
www.inotivco.com
Inotiv Metrics
BasicAdvanced
$51M
Market cap
-
P/E ratio
-$2.78
EPS
3.30
Beta
-
Dividend rate
Price and volume
Market cap
$51M
Beta
3.3
Financial strength
Current ratio
0.367
Quick ratio
0.204
Long term debt to equity
18.098
Total debt to equity
207.212
Interest coverage (TTM)
-0.81%
Management effectiveness
Return on assets (TTM)
-2.67%
Return on equity (TTM)
-30.12%
Valuation
Price to revenue (TTM)
0.092
Price to book
0.25
Price to tangible book (TTM)
-0.29
Price to free cash flow (TTM)
5.319
Growth
Revenue change (TTM)
-7.47%
Earnings per share change (TTM)
-79.43%
3-year revenue growth (CAGR)
100.89%
3-year earnings per share growth (CAGR)
101.10%
What the Analysts think about Inotiv
Analyst Ratings
Majority rating from 3 analysts.
Inotiv Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$119M
-12.18%
Net income
-$48M
213.73%
Profit margin
-40.33%
257.22%
Inotiv Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
$0.07
-$0.38
-$0.60
-$1.86
-
Expected
-$0.10
-$0.33
-$0.86
-$0.54
-$0.84
Surprise
-170.00%
15.15%
-29.82%
244.44%
-
Inotiv News
AllArticlesVideos
Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024
GlobeNewsWire·2 days ago
Inotiv, Inc. Provides Business Updates
GlobeNewsWire·2 months ago
Inotiv Reaches Agreement to Resolve Previously-Announced Investigation into Shuttered Cumberland Facility
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inotiv stock?
Inotiv (NOTV) has a market cap of $51M as of July 27, 2024.
What is the P/E ratio for Inotiv stock?
The price to earnings (P/E) ratio for Inotiv (NOTV) stock is 0 as of July 27, 2024.
Does Inotiv stock pay dividends?
No, Inotiv (NOTV) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Inotiv dividend payment date?
Inotiv (NOTV) stock does not pay dividends to its shareholders.
What is the beta indicator for Inotiv?
Inotiv (NOTV) has a beta rating of 3.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Inotiv stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.